ArticleResearch and practice in thrombosis and haemostasis2025
Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes.Research and practice in thrombosis and haemostasis · 2026Article
- Adherence of Oncologists and Cardiologists to Venous Thromboembolic Disease Prevention and Treatment Guidelines in Cancer Patients: A Cross-Sectional Survey from Turkey.Journal of clinical medicine · 2026Article
- Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.ESMO open · 2026Article
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer.Frontiers in oncology · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Implementation failure: thromboprophylaxis in ambulatory patients with cancer.Hematology. American Society of Hematology. Education Program · 2025Review
- Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism remains a major cause of morbidity and mortality among ambulatory cancer patients, necessitating effective risk assessment and prevention strategies. Despite the availability of risk assessment models and guidelines recommending primary thromboprophylaxis with low-molecular-weight heparins or direct oral anticoagulants, the application of these strategies is inconsistent. This review provides an overview of the current state-of-the-art venous thromboembolism risk assessment and thromboprophylaxis in ambulatory patients with cancer, focusing on existing risk assessment models and the latest guideline recommendations. Finally, it summarizes gaps in knowledge, discusses future directions, and highlights recent advances and state-of-the-art research presented at the 2024 International Society on Thrombosis and Haemostasis Congress in Bangkok, Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.